changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
The TheraSphere® READ90Y™ registry is an observational, prospective global study.
READ90Y™ is the first TheraSphere® registry designed to address data gaps and provide valuable insights into the management of liver cancer in a real world clinical practice setting following TheraSphere® treatment.
The registry will capture the effectiveness and safety of TheraSphere® in the diversity of disease presentation, treatment modalities and intention to treat decision-making to inform future treatment considerations.
Approximately 25 academic and community-based centers across the U.S, Canada, Europe and Asia will be participating in the READ90Y™ registry. The enrollment target for the registry is 1000 patients with dosimetry data, using the Simplicit90Y™ software, collected from 300 HCC patients.
Patient recruitment is ongoing and expected to last approximately 3 years and the entire study 5 years.
More information can be found on www.clinicaltrials.gov; NCT03516695